Hybio Pharmaceutical Co., Ltd.
300199
Classifica tra le azioni
#4739
Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical... Established in 1998 and headquartered in Shenzhen, China, Hybio Pharmaceutical Co., Ltd. specializes in the global research, development, manufacturing, and commercialization of therapeutic peptide active pharmaceutical ingredients (APIs) and polypeptide medications. Its diverse product range addresses therapeutic needs such as diabetes (including liraglutide, semaglutide, and exenatide), gastrointestinal and metabolic disorders (with examples like terlipressin, desmopressin, and linaclotide), as well as applications in obstetrics and gynecology (featuring ganirelix, cetrorelix, and atosiban). Additionally, the company supplies custom peptides and provides essential working standards for peptide APIs and their impurities, offering comprehensive support for development initiatives. Beyond products, Hybio extends its expertise through Contract Research Organization (CRO) and an extensive Contract Development and Manufacturing Organization (CDMO) platform. This platform covers peptide API synthesis and purification process optimization, finished dosage form conceptualization, reference standard preparation and rigorous qualification, detailed impurity and product quality analysis, Good Manufacturing Practice (GMP) systems adhering to both EU and FDA benchmarks, and comprehensive regulatory and dossier support for both international and Chinese markets.
Prezzo delle azioni
$3.69
Capitalizzazione di mercato
$3.11B
Variazione (1 giorno)
-7.75%
Variazione (1 anno)
21.56%
Paese
CN
Scambia Hybio Pharmaceutical Co., Ltd. (300199)
Categoria
Healthcare
Utile per Hybio Pharmaceutical Co., Ltd. (300199)
Utile nel Jun 2026 TTM: $23.66M
Secondo gli ultimi rapporti finanziari di Hybio Pharmaceutical Co., Ltd., gli utili attuali della società sono $23.66M. Nel 2024, la società ha registrato un utile di $-22.25M, un aumento rispetto a agli utili del 2023, che erano di $-72.20M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Hybio Pharmaceutical Co., Ltd. dal 2007 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $23.66M | 157.76% |
| 2025 | $9.18M | -141.26% |
| 2024 | $-22.25M | -69.18% |
| 2023 | $-72.20M | 33.59% |
| 2022 | $-54.05M | -1,119.96% |
| 2021 | $5.30M | -105.88% |
| 2020 | $-90.05M | -29.65% |
| 2019 | $-128.00M | 163.83% |
| 2018 | $-48.52M | -190.05% |
| 2017 | $53.88M | 20.99% |
| 2016 | $44.53M | -14.53% |
| 2015 | $52.11M | 73.20% |
| 2014 | $30.08M | 23.42% |
| 2013 | $24.38M | 44.61% |
| 2012 | $16.86M | 13.35% |
| 2011 | $14.87M | 79.07% |
| 2010 | $8.30M | 48.60% |
| 2009 | $5.59M | 70.78% |
| 2008 | $3.27M | 57.76% |
| 2007 | $2.07M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $3.62B | 15,188.96% |
DE
|
|
| $3.40B | 14,289.34% |
DE
|
|
| $1.72B | 7,183.94% |
JP
|
|
| $930.30M | 3,831.42% |
CH
|
|
| $1.76B | 7,356.94% |
IN
|
